trending Market Intelligence /marketintelligence/en/news-insights/trending/lG5AQS0Gedj2MAxycE2vaw2 content esgSubNav
In This List

Cascadian Therapeutics to raise $82.5M in public offerings

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Cascadian Therapeutics to raise $82.5M in public offerings

Cascadian Therapeutics Inc. is looking to raise approximately $82.5 million in two concurrent underwritten offerings.

The company priced an offering of 23,182,000 common stock at $3.30 apiece to raise $76.5 million; Cascadian will also issue 1,818 series E preferred stock at $3,300 per share to raise another $6 million.

Each series E preferred stock is convertible into 1,000 Cascadian shares. Underwriters have an option to purchase an additional 3,477,300 of the shares offered.

The offering is expected to close Jan. 27 and will help fund the clinical trial of Tucatinib for the treatment of breast cancer.

Cowen and Co. LLC and Barclays Capital Inc. are acting as joint book-running managers of the issue, with Raymond James & Associates Inc. acting as lead manager and BTIG LLC acting as a co-manager.